Asahi Kasei Therapeutics Venture Capital

Profile and portfolio

Parent Asahi Kasei TherapeuticsFounded 2018

Asahi Kasei Therapeutics Venture Capital is the corporate venture arm of Asahi Kasei Therapeutics, a pharmaceutical and biotech company. It was founded in 2018. It invests from seed to Series A. Sectors it names: biotech and life sciences.

Companies backedS1: 6+

Every figure links to its source

Snapshot

Investment stage: Seed to Series A

Data behind this graphic

Data behind this graphic
Item	Value
Stage range	Seed to Series A
Sectors	Biotech and life sciences
Geography	North America, Europe, Asia, Middle East and Africa
Offices	Chelmsford, United States, Tokyo, Japan

Sources: S1 Asahi Kasei Therapeutics: Corporate Venture Capital.

Scale and capital allocated

Data behind this graphic

Data behind this graphic
Measure	Value	Unit	Kind	Source
Companies backed	6+	companies	Stated by the firm	S1
Companies on the firm's portfolio page	6	companies	Counted from the firm's own list	S1

Sources: S1 Asahi Kasei Therapeutics: Corporate Venture Capital.

Where it invests

Geography

Offices: Chelmsford, United States
Tokyo, Japan

Investment regionsS1

Key facts

Fact	Value	Status	Source
Parent company	Asahi Kasei Therapeutics	Single source	S1
Parent industry	Pharmaceuticals and biotech	Single source	S1
Founded	2018	Single source	S1
Status	Active	Single source	S1
Capital source	Parent company only	Single source	S1
Companies backed	6+	Single source	S1
Stages	Seed, Series A (inferred from announced rounds)	Estimate	S1

For founders

Item	What the firm says	Source
Stages	Seed, Series A. Inferred from announced rounds; the firm does not state a range.	S1
Beyond capital	Access to the Open Innovation Center for proof of concept experiments	S1

History

2018Fund formedS1

Portfolio

The firm's portfolio page lists 6 companies.S1

Shared portfolio with other corporate VCs

6 companies on the Asahi Kasei Therapeutics Venture Capital portfolio page also appear on the portfolio page of at least one other firm in this directory. Matched by company website, or by name where no website is published.

Firm	Shared	Companies in common
Asahi Kasei Ventures	6	Glycomine, Allievex, Azafaros, Curreio, LUCA Science, Pulmocide
Chiesi Ventures	1	Glycomine
Sanofi Ventures	1	Glycomine
LG Technology Ventures	1	Allievex

Companies backed by the most corporate VCs

Every company on the Asahi Kasei Therapeutics Venture Capital list

6 companies, as listed on the firm's own website.S1 Read the firm's list.

Allievex
Azafaros
Curreio
Glycomine
LUCA Science
Pulmocide

Official pages

Read the firm's own pages for current information.

Website www.asahi-kasei.co.jp/pharma/en/corporate_vc/

Sources

S1Asahi Kasei Therapeutics: Corporate Venture CapitalFirm

Disclaimer and corrections

Not affiliated. This page is not affiliated with, endorsed by or sponsored by Asahi Kasei Therapeutics Venture Capital or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.

Spotted a mistake? Report a correction.

Report a correction